JW Pharmaceutical shares climbed as much as 16.95% to 30,700 won by 9:05 a.m. KST on Aug. 12 after the company released successful Phase 3 results for epaminurad and stronger standalone second-quarter earnings. Revenue rose 16.1% from a year earlier to 220.2 billion won, operating profit increased 32.7% to 33.7 billion won, and net income returned to profit at 27 billion won. In a 612-patient trial across 52 sites in South Korea, Taiwan, Thailand, Malaysia and Singapore, the oral hURAT1 inhibitor met the primary endpoint in its 6 mg arm, with 50.0% of patients reducing serum uric acid below 6 mg/dL at the final three measurements versus 38.3% for febuxostat 40 mg, establishing non-inferiority and statistical superiority. The 9 mg arm did not meet non-inferiority against febuxostat 80 mg, though safety outcomes were broadly similar across groups. JW Pharmaceutical plans to seek South Korean marketing authorization next year, after previously saying it had completed two pre-NDA meetings with the Ministry of Food and Drug Safety, while continuing to pursue overseas partnerships.